

## Disclosure:

Piervincenzi has received grants or contracts from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. Preziosa has received grants or contracts from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla; and payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Roche, Genzyme, Biogen, Horizon, Novartis, Sanofi, Merck, and Bristol Myers Squibb. Rocca has received grants or contracts from the MS Society of Canada, Fondazione Italiana Sclerosi Multipla, the Italian Ministry of Health, and the Italian Ministry of University and Research; consulting fees from Biogen, Roche, Bristol Myers Squibb, Eli Lilly, and Janssen; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from AstraZeneca, Horizon Therapeutics Italy, Biogen, Merck Serono, Bristol Myers Squibb, Novartis, Bromatech, Roche, Celgene, Sanofi, Genzyme, and Teva; and has served as Associate Editor for Multiple Sclerosis and Related Disorders and Associate Co-Editor for Europe and Africa for Multiple Sclerosis Journal. Storelli has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Biogen. Cortese was awarded a MAGNIMS-ECTRIMS fellowship in 2019, has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Roche, Merck-Serono, and Sanofi; and support for attending meetings and/or travel from Novartis. De Stefano has received grants or contracts from Fondazione Italiana Sclerosi Multipla and Novartis; consulting fees from Biogen, Roche, Merck, Teva, Novartis, and Sanofi-Genzyme; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Biogen, Merck, Novartis, Sanofi-Genzyme, and Teva; support for attending meetings and/or travel from Merck, Sanofi-Genzyme, Novartis, Teva, and Roche; and is co-founder of Siena Imaging s.r.l.. Filippi has received grants or contracts from Biogen Idec, Roche, Merck-Serono, the Italian Ministry of Health, Novartis, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla; consulting fees from Almirall, Merck, Biogen, Novartis, Bristol-Myers Squibb, Roche, Eli Lilly, and Sanofi; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Amgen, Eli Lilly, Bayer, Fujirebio, Biogen, Genzyme, Bristol-Myers Squibb, Janssen, Celgene, Merck, Chiesi Italia SpA, Neopharmed Gentili, Eisai, Neuraxpharm, Novartis, Roche, Novo Nordisk, Sanofi, and Takeda; has participated on Data Safety Monitoring Boards or Advisory Boards for Alexion, Neuraxpharm, Biogen, Novartis, Bristol-Myers Squibb, Roche, Eli Lilly, Sandoz, GE Healthcare Ltd, Sanofi, Merck, and Takeda; has served as Editor-in-Chief of Journal of Neurology, Associate Editor of Radiology, Associate Editor of Human Brain Mapping, and Associate Editor of Neurological Sciences; and has provided scientific direction for educational events for Biogen, Merck,

Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, and Sanofi-Genzyme. Gallo has received grants or contracts from the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla; and consulting fees and payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Alexion, Janssen, Biogen, Juvisè Pharmaceuticals, Bristol Myers Squibb, Merck Serono, Genzyme, Mylan, Novartis, Roche, and Teva. Jain has received funding from the Multiple Sclerosis International Federation andECTRIMS in the form of an MSIF-ECTRIMS McDonald Fellowship. Pantano has received grants or contracts from the Italian Ministry of Foreign Affairs, the Italian Ministry of Health, and Fondazione Italiana Sclerosi Multipla; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Biogen; and support for attending meetings and/or travel from Novartis, Genzyme, and Bracco. The remaining authors have declared no conflicts of interest.